<i>TET2</i> Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Klaus H. Metzeler(University Hospital Leipzig), Clara D. Bloomfield(North Shore University Hospital), Kati Maharry(Peter MacCallum Cancer Centre), Kelsi B. Holland(University of Iowa), Heiko Becker(University of Freiburg), Meir Wetzler, Michael D. Radmacher, Michael A. Caligiuri(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Maria R. Baer(University of Maryland, Baltimore), Guido Marcucci(City of Hope), Jonathan E. Kolitz(Memorial Sloan Kettering Cancer Center), Thomas H. Carter(University of Iowa), Richard A. Larson(Urbana University), Andrew J. Carroll(University of Alabama at Birmingham), Joseph O. Moore(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Krzysztof Mrózek(The Ohio State University), John Curfman(University of Maryland, Baltimore), Dean Margeson(University of Iowa), Bayard L. Powell(Atrium Health Wake Forest Baptist), Susan P. Whitman(The Ohio State University Wexner Medical Center), Sebastian Schwind, Yue-Zhong Wu(University of Iowa), William Blum(The Ohio State University)
Cited by 321
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k